| abstract |
The present invention relates to novel compounds as inhibitors of acyl-CoA:diacylglycerol acyltransferase 1 (DGAT-1), pharmaceutical compositions containing them, processes for their preparation and their function in the prevention or treatment of DGAT-1 Use in therapy of disorders related diseases or diseases in which modulation of DGAT-1 activity may be of therapeutic benefit, including but not limited to obesity, obesity related diseases, hypertriglyceridemia, hyperlipoproteinemia , chylomicronemia, dyslipidemia, nonalcoholic steatohepatitis, diabetes mellitus, insulin resistance, metabolic syndrome, hepatitis C virus infection, and acne or other skin conditions. |